According to a Reuters report, UBS Group AG (UBS) is in discussions to form an Indian wealth management joint venture (JV) with 360 One WAM, a Mumbai-based firm, formerly known as IIFL Wealth Management.UBS is in preliminary discussions with 360 One WAM to acquire around 26% stake in the JV. The deal is expected to be finalized in the upcoming months. This potential JV is expected to expand UBS’ Indian wealth management business to high-net-worth individuals in addition to its existing ultra-high-net-worth ...

文章核心观点 - UBS Group AG 于 2024 年 9 月 18 日减持了 Solvay SA 的股票,导致其持股比例从 3% 以上下降至 3% 以下 [1] - 这是由于 UBS 旗下的受控实体减少了交易账户中的 Solvay 股票持仓,导致总持股比例下降至 3% 以下,从而触发了信息披露义务 [1] 根据相关目录分别进行总结 持股变动情况 - UBS Group AG 在 2024 年 9 月 18 日减持了 Solvay SA 的股票 [1] - 导致 UBS 集团在 Solvay 的总间接持股比例从 3% 以上下降至 3% 以下 [1] 持股比例变动原因 - 这是由于 UBS 旗下的受控实体减少了交易账户中的 Solvay 股票持仓 [1] - 交易账户中的 Solvay 股票持仓下降至 5% 以下,从而不再需要进行信息披露 [1] 其他信息 - Solvay 的总股本为 105,876,416 股 [1] - UBS Group AG 的注册地址为瑞士苏黎世 [1]

TORONTO, Sept. 26, 2024 (GLOBE NEWSWIRE) -- Xtract One Technologies (TSX: XTRA)(OTCQX: XTRAF)(FRA: 0PL) (“Xtract One” or the “Company”), a leading technology-driven threat detection and security solution that prioritizes the patron access experience by leveraging AI, today announced that its SmartGateway screening solution was selected to secure UBS Arena in New York. This contract is enabled through the Company’s partnership with Oak View Group (OVG), a global sports and entertainment company. UBS Arena, a ...

IRVINE, Calif., Sept. 25, 2024 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), whose mission is to focus on unmet needs and apply proven science and new technology to revolutionize treatment for patients, starting with eye care, today announced that Aziz Mottiwala, Chief Commercial Officer, will participate in a virtual fireside chat at the UBS Virtual Ophthalmology Day 2024 taking place on Wednesday, October 2, at 6:00 a.m. PT / 9:00 a.m. ET. A live webcast and additional information about ...

BEDFORD, Mass., Sept. 25, 2024 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular”, the “Company”), a biopharmaceutical company committed to improving vision in the real world through the development and commercialization of innovative therapies for retinal diseases and other eye conditions, today announced that it will participate in the UBS Virtual Opthalmology Day 2024: UBS Virtual Opthalmology Day 2024Fireside Chat Date: Wednesday, October 2, 2024Presentation Time: 3:00 PM ETOcular Pres ...

Jordan FinnesethJordan Finneseth is a Crypto Market Reporter for Kitco Crypto. Coming from a background in Psychology and Human Behavior, he began to focus his attention on the cryptocurrency space in early 2017 after noticing the rapid growth of this emerging market. Since that time, Jordan has worked as a content creator for multiple projects and as a crypto news journalist reporting on the latest developments within the cryptocurrency market. Jordan holds a Master of Science in Clinical/Counseling Psycho ...

A month has gone by since the last earnings report for UBS (UBS) . Shares have lost about 3.9% in that time frame, underperforming the S&P 500.Will the recent negative trend continue leading up to its next earnings release, or is UBS due for a breakout? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at the most recent earnings report in order to get a better handle on the important catalysts. UBS Group Q2 Earnings Fall Y/Y on Higher Costs, Revenues UpUBS Grou ...

The CEO of Swiss banking giant UBS said Thursday that the fight against inflation isn't over yet, and some investors seem to be getting too ahead of themselves in expecting that the U.S. Federal Reserve could pull an aggressive rate cut this month."I think the market seems to be a little bit too ahead of the curve in expecting the Fed to go so aggressively,"  Sergio Ermotti, Group CEO of UBS Group AG, told CNBC's "Squawk Box Asia."The question of whether the Fed will lower rates at the end of its next polic ...

文章核心观点 - 瑞士央行行长表示,瑞银集团(UBS)应该增加资本储备,以应对即将到来的监管变化,这些变化被认为对于防止瑞士信贷(Credit Suisse)2023年发生的崩溃至关重要 [1] - 美联储也采取类似的方法,要求美国银行进行压力测试,以应对潜在的崩溃 [1] - 瑞银集团完成收购瑞士信贷后,其资产管理业务的营业利润大幅增长,突出了此次收购对瑞银财务状况的积极影响 [2] - 瑞银集团表示,新的资本要求可能需要它筹集150亿至250亿美元的额外资本,这些新要求旨在防止出现类似瑞士信贷崩溃的问题 [3] - 瑞士金融市场监管局(Finma)希望获得新的权力,包括在危机前干预银行的业务模式,对高管决策进行罚款和否决 [4] - 瑞士央行行长强调了三个银行体系中必须确保的重要因素:准确的资本估值、适当的资本分配以及可转换资本的无障碍转换 [5] 根据目录分别总结 瑞银集团的资本状况 - 2024年6月30日,瑞银集团的普通股一级(CET1)资本比率为14.9%,CET1杠杆比率为4.9% [2] - 管理层预计到2026年底和2028年底,瑞银的CET1资本回报率将分别达到约15%和18% [2] 新的资本要求 - 瑞士央行计划要求瑞银集团持有更多资本,瑞银可能需要筹集150亿至250亿美元的额外资本 [3] - 这些新要求旨在防止出现类似瑞士信贷崩溃的问题 [3] - 瑞士央行行长表示,瑞银不会被要求立即持有额外股权,而是会被给予足够的时间进行调整 [3] 监管改革 - 改革将加强金融监管机构Finma的权力,包括在危机前干预银行的业务模式,对高管决策进行罚款和否决 [4] - 这些改革旨在加强银行的公司治理、流动性和资本持有,但可能需要几年时间才能完全实施 [4] 瑞士央行行长的观点 - 准确的资本估值、适当的资本分配以及可转换资本的无障碍转换是银行体系中必须确保的三个重要因素 [5] - 这些措施反映了瑞士致力于建立更有抗风险能力的银行业,将采取前瞻性的监管方式 [5]

文章核心观点 - 公司是一家专注于提供金融新闻和在线广播的公司,拥有遍布全球主要金融中心的新闻团队 [1][2] - 公司专注于中小市值公司,同时也关注蓝筹股、大宗商品和新兴数字技术等更广泛的投资故事 [2] - 公司采用人工智能等技术辅助内容创作,但所有内容仍由人工编辑和撰写 [3] 公司概况 - 公司拥有15年以上的资本市场报道经验,尤其擅长报道小型资源股 [1] - 公司的新闻团队遍布全球主要金融中心,包括伦敦、纽约、多伦多、温哥华、悉尼和珀斯 [2] - 公司提供涵盖生物科技、采矿、电池金属、石油天然气、加密货币和新兴电动车技术等领域的独特洞见 [2] 技术应用 - 公司积极采用前沿技术,包括自动化和生成式人工智能等工具,以提高内容创作效率 [3] - 但所有内容仍由公司的人工编辑和撰写团队进行编辑和创作,确保内容质量 [3]